Diversified PET/MR differentiates more breast lesions

Using a multiparametric (MP) approach, PET/MR imaging with F-18 FDG, dynamic contrast-enhanced MRI (DCE-MRI), diffusion-weighted imaging (DWI) and 3-D proton MR spectroscopic imaging (3D H-MRSI) is superior for telling apart different kinds of breast tumors, according to a study published online June 24 in Clinical Cancer Research.

Thomas H. Helbich, MD, from the department of biomedical imaging and image-guided therapy in the division of molecular and gender imaging at the Medical University of Vienna, Austria, and colleagues assessed the four-part PET/MR scan in the study of 75 female patients with a spectrum of 53 malignant and 23 benign breast lesions. They found that having multiple parameters improved detection of both malignant and benign tumors.

This MP-PET/MR approach was 96 percent accurate for differentiating benign and malignant growths and using two or three parameters was determined to be the best practice. Compared to DCE-MRI alone, using this MP technique could cut down on as much as 50 percent of unnecessary breast biopsies.

“This feasibility study shows that MP F-18 FDG PET-MRI enables an improved differentiation of benign and malignant breast tumors when several MRI and PET parameters are combined. MP F-18 FDG PET-MRI may lead to a reduction in unnecessary breast biopsies,” concluded the authors.

Around the web

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.